First of, Alzheimer’s and Parkinson’s are prion-diseases. Prions are like HIV in AIDS. Once science identified HIV, successful treatments for AIDS were found.
We’re working to replicate this treatment success for Alzheimer’s and Parkinson’s diseases.
Our mission is to track the prions EARLY — decades before they destroy the brain. When symptoms start to appear, this is late stage of Alzheimer’s or Parkinson’s. It is too late as the brain has been destroyed.
To find successful treatments for Alzheimer’s and Parkinson’s, we must detect these diseases early. As early as possible. And with certainty.
According to the Alzheimer’s Association, delaying the onset of Alzheimer’s by just 5 years could decrease the number of people with active disease by as much as 42%
Amprion’s breakthrough Prion Early Detection Testing℠ provides accurate tracking of the Prions that drive Alzheimer’s and Parkinson’s prior to any clinical symptoms.
For people who are worried about early onset of memory, motor or cognitive decline, Amprion’s technology can help rule out the existence of Prions, thus reducing unnecessary stress.
For people who have positive test results, you and your doctor may choose to initiate medical and/or lifestyle changes to delay—or avert—loss of memory or independence.
Memory loss or movement disorders are often indications of irreversible damage in Alzheimer’s and Parkinson’s.
Intervention before these symptoms occur is the key in delaying Alzheimer’s disease.
Amprion’s Prion Early Detection Testing can track the levels of Prions in the brain to help determine if lifestyle changes can slow down Alzheimer’s and Parkinson’s before clinical symptoms occur.
A Global Health Crisis
Aging is a global phenomenon. The number of people affected by Alzheimer’s and Parkinson’s around the world is growing at an alarming rate. Yet there is no cure so far.
In the US alone, of the 50 million people over 65, it is estimated that approximately 19.5%–or almost 10 million–show symptoms consistent with the earliest form of cognitive impairment. As many as one-third of these people will improve over time, while approximately one-third will progress quickly to dementia and the remaining one-third will remain mildly to moderately impaired.
A 2016, survey of 403 US physicians actively diagnosing or treating Alzheimer’s (published by Medscape) indicated that while only 29% of physicians surveyed believed that the onset of Alzheimer’s could be prevented, 77% believed that progression could be slowed by lifestyle changes. In addition, 74% of physicians believed that Alzheimer’s is due to “Beta-amyloid/tau proteins propagating in a prion-like manner”. (The State of Alzheimer Disease Care: Physicians Weigh In Bret S. Stetka, MD; Gary W. Small, MD | February 24, 2016.)
For some people, the disease progresses quickly, for others the progression is slow. Some could have symptoms first appear when they are in their 70’s (if not earlier), while others might not show symptoms until their 90’s.
Conclusion: Prions in Alzheimer’s and Parkinson’s affect everyone differently.
Ten different people could have ten different outcomes. This is in part why neurodegenerative diseases are so difficult to treat.
This is what drives us daily in our work—to find scalable, replicable, and cost-effective solutions to personalized brain health.